1520O REGISTRI: Regorafenib in first-line of KIT/PDGFR wild type advanced GIST: Capatalize the A Spanish (GEIS), Italian (ISG) and French Sarcoma Group (FSG) phase II trial
Sign Up to like & getrecommendations! Published in 2021 at "Annals of Oncology"
DOI: 10.1016/j.annonc.2021.08.850
Abstract: Background: Around 15% of adult GIST are wild type for KIT/PDGFRA mutations (KPWT), usually have SDH deficiencies, and are resistant to imatinib (IM). The underlying mechanisms include overexpression of HIF1α in SDH deficient-GIST, high IGFR… read more here.
Keywords: invited speaker; research; interests institutional; institutional invited ... See more keywords